PALM BEACH, Florida, Feb. 26, 2020 /PRNewswire/ -- When caught early enough, the five-year survival rates are 99%, says the American Cancer Society. However, early detection is essential, which is why experts strongly advised screening. After all, "Where the breast cancer is located, where it has spread to, how big it is—all that plays a role in different treatment options for patients," says Dr. Keith Wells, a medical oncologist at Willamette Valley Cancer Institute, as quoted by KVAL13. To assist patients, companies are racing to produce cost-effective screening methods that offer greater accuracy, speed, and comfort than traditional methods. As you might expect, the market for breast imaging with existing methods has been big. In fact, according to Meticulous Research, the global breast imaging market will be worth up to $5.13 billion, growing at a CAGR of 8.2% over the next four years. Some of the top companies leading the fight for better cancer detection include Izotropic Corporation (CSE:IZO)(OTCPK: IZOZF), Hologic Inc. (NASDAQ:HOLX), Stryker Corporation (NYSE:SYK), NeGenomics Inc. (NASDAQ:NEO), and Clovis Oncology Inc. (NASDAQ:CLVS).
Izotropic Corporation (CSE:IZO)(OTCPK: IZOZF) BREAKING NEWS: Izotropic Corporation has extended the terms of its exclusive global License Agreement with The Regents of the University of California. The amendments under the revised exclusive global License Agreement relate to the formal Commercialization Plan of breast CT technology developed at UC Davis Medical Center in Sacramento, CA. Due to unforeseen delays with patent prosecutions and completing important patent applications and filings, there was mutual desire by the parties to negotiate an extension. The Company now has until January 2027 to execute on the terms agreed to under the Commercialization Plan and expects to meet the terms of the Commercialization Plan under the Licensing Agreement well before this date. In consideration of this extension, a nominal payment of $20,000 per annum will be made until commercialization terms are completed. Extending the commercialization terms and timeline is a material development for the Company and we wish to acknowledge the support and cooperation provided by the Regents of the University of California and UC Davis.
Other related developments from around the markets include:
Contact Information:
Media Contact email:
[email protected]
+1(561)325-8757
SOURCE FinancialNewsMedia.com
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
